APPLICATION

Predicting Drug-Induced Vascular Injury (DIVI)

Drug-induced vascular injury stalls drug development programs, while no qualified clinical biomarkers exist to follow up in patients, and preclinical work in animals lacks translatability. At MIMETAS we have developed an extensive array of human-relevant solutions to investigate DIVI. Choose between OrganoReady® assay-ready plates, an outsourced and standardized OrganoServices study, or fully customized projects.

MIMETAS’ Solutions for DIVI

Sensitive
Capable of flagging known vascular-toxic drugs using OrganoReady Blood Vessel HUVEC
Flow enabled
Quantify immune cell activation and adhesion or vasoconstriction and dilation under flow
Industry leading
Developed by Takeda for oligonucleotide-induced thrombocytopenia
THE CHALLENGE

Conventional Models Miss Vascular Liabilities.
MIMETAS’ Solutions Bring Them Into View.

DIVI is a recognized cause of compound termination, with a particular risk for vasoactive drugs, anticancer agents and biologics, like antibodies. It presents as vascular leakage, hemorrhage, inflammation, thrombosis or arterial lesions, and each of these can independently stall a program. MIMETAS’ platforms recreate a perfused, polarized, leak-tight human endothelial tube, so you can see how your compound affects the vessel wall under flow. Apical (lumen) and basolateral access let you dose from the blood side or the tissue side in the same assay.

Conventional Models
Poor translational concordance. Animal vascular findings can be of uncertain relevance to patients, and animal models poorly predict cardiovascular adverse events.
Limited physiological relevance. Transwell models lack shear stress and show high barrier leakiness with poor TEER measurement.
Difficult to quantify immune activation. Monocyte adhesion, activation and migration are difficult to capture on Transwell, and no validated clinical biomarker exists.
MIMETAS’ Solutions for DIVI
Direct human relevance. Adaptable to various endothelial cell types and smooth muscle cells in a perfused 3D tube.
Recapitulate functional vasculature. Leak-tight tube with apical perfusion under flow and basolateral access. Real-time monitoring of barrier integrity.
Enable quantitative measurements of immune endpoints. Robust monocyte/PBMC perfusion and quantification, direct imaging, and multiplexed readouts: TEER, ATP, LDH, adhesion, cytokines.
WHAT YOU CAN STUDY

Four Routes to Vascular Injury,
One Platform

DIVI is not a single event. Compounds can injure the endothelium directly, trigger immune activation, activate platelets, or disturb vascular tone. Each demands a different solution. MIMETAS lets you investigate each of them, with the model and access route that fits.

01

Direct endothelial injury

Clinical manifestation: vascular leakage, hemorrhage

Get real-time barrier readouts alongside viability, from a 5-day acute assay up to 8-week chronic exposure, and uncover time-dependent toxicity that short or static assays miss, using a perfused, leak-tight vessel with apical and basolateral access.

1
Acute assay

In the standardized acute assay, tubes are exposed from both the apical and basolateral side for 5 days with one re-dosing, and barrier integrity (OrganoTEER®) and viability (ATP) are reported as EC50 values.

2
Chronic exposure

For chronic exposure, the vascular bed in the OrganoPlate® Graft UniFlow, available via our OrganoAccess™ program, sustains unidirectional perfusion for up to 8 weeks.

02

Immune activation

Clinical manifestation: inflammation

Quantify immune cell adhesion directly and separate endothelial activation from toxicity in the same model, using an imageable tube where immune cells adhere under physiological flow.

PLACEHOLDER 05_immune-activation
1

Stimulate the endothelium or immune cells

2

Perfuse labelled immune cells

3

Quantify adhesion under flow

03

Platelet activation

Clinical manifestation: thrombosis, thrombocytopenia

Assess platelet aggregation in its vascular context rather than in isolation, by perfusing platelets over a human endothelium.

PLACEHOLDER 06_platelet-activation

In a platelet-perfused endothelium model developed by Takeda on the MIMETAS platform, oligonucleotide-induced thrombocytopenia was reproduced and quantified by CD41-positive aggregate formation in a dose-dependent manner (Harada et al., 2024).

04

Vasoactive pharmacology

Clinical manifestation: arterial lesions, hemorrhage

Read out vasoconstriction and dilation directly, capturing vessel tone that endothelium-only models cannot show, using smooth muscle cells layered around the endothelium under unidirectional flow.

PLACEHOLDER 07_vasoactive-pharmacology

Cytokine-induced inflammation strongly induces vasoconstriction in a co-culture of human coronary artery endothelial cells (HCAEC) with smooth muscle cells (HCASMC) on the OrganoPlate® UniFlow.

HOW TO WORK WITH US

Three Ways to
Get Started

Whether you want to run it yourself, hand it to us, or design something custom, we have you covered.

PRODUCT
OrganoReady® Blood Vessel HUVEC
Assay-ready, flow-perfused endothelial tubes for in-house DIVI assays on the OrganoPlate®
  • Apical and basolateral access
  • Easy TEER and medium sampling
  • Robust monocyte perfusion
  • From order to results in about 4 weeks, including a 14-day assay window.
SERVICES
OrganoServices DIVI
We run the validated assay for you.

Test induction of endothelial toxicity for any compound with out standardized services
  • Fully functional HUVEC tubes
  • 5-day compound exposure
  • Robust quantification of viability and barrier integrity
SERVICES
Custom Services
Need a different model or endpoint? We tailor the study with you
  • Co-cultures, including with multiple donors
  • Healthy or diseased tissue
  • Tissue-specific endothelia (HUVEC, HBMEC, HCAEC)
  • Co-development of new clinically relevant readouts
Chronic exposure studies run via OrganoAccess.
Not sure which option fits your program? Talk to a scientist: no sales pitch, just a conversation about your compound and timeline.
TRUSTED PARTNER

Trusted Partner and Customer Voices

  • >10 years of relationships with leading pharmaceutical companies
  • >200 projects across all phases of drug development
PLACEHOLDER 09_trusted-partner-logos

Ready to Get Started?

Ship your compound and get a structured, human-relevant vascular safety report, typically within a week of assay completion.

Need more info? Contact us